产品
编 号：F201951
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1690318-25-2
产品详情
生物活性：
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.
体内研究：
Crizanlizumab (1 或 6 mg/kg，腹膜内注射，每周 3 天，持续 5 个月) 可改善 4 周龄雄性 HbSS (镰状细胞病) 小鼠的镰状细胞性视网膜病变。
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.
体内研究：
Crizanlizumab (1 或 6 mg/kg，腹膜内注射，每周 3 天，持续 5 个月) 可改善 4 周龄雄性 HbSS (镰状细胞病) 小鼠的镰状细胞性视网膜病变。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备